Pacific Biosciences of California, Inc.
PACBHealthcareNASDAQMedical Devices · Last scanned Jun 2, 2026
Scan Results
Daily timeframePart of the healthcare sector, Pacific Biosciences of California, Inc. (PACB) is listed under Medical Devices. With a market capitalization of $490.8M, it sits in small-cap territory. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Market Cap
$490.8M
Beta
2.40
P/E (TTM)
—
P/E (Fwd)
-3.93
EPS (TTM)
$-0.41
EPS (Fwd)
$-0.40
ROE
-273.6%
ROA
-12.0%
Cash
$276.0M
Total Debt
$706.4M
Free CF
-$48.2M
52W Change
50.5%
Annual Financials
Cash vs Debt
The company holds $276.0M in cash, though total debt stands at $706.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$48.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -273.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $128.3M (2022) to $160.0M (2025), reflecting a 25% increase over the period.
A beta of 2.40 means PACB is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Pacific Biosciences of California, Inc. and its sector.